Insulet (NASDAQ:PODD) Releases Earnings Results, Beats Estimates By $0.11 EPS

Insulet (NASDAQ:PODD) issued its quarterly earnings data on Thursday. The medical instruments supplier reported $1.24 earnings per share for the quarter, topping the consensus estimate of $1.13 by $0.11, Zacks reports. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The firm had revenue of $521.70 million for the quarter, compared to analysts’ expectations of $678.70 million. During the same period in the prior year, the firm earned $1.08 earnings per share. The company’s quarterly revenue was up 29.9% compared to the same quarter last year. Insulet updated its FY 2025 guidance to EPS and its Q4 2025 guidance to EPS.

Insulet Trading Down 1.1%

Shares of Insulet stock traded down $3.58 on Friday, hitting $319.82. 677,166 shares of the company’s stock traded hands, compared to its average volume of 721,278. Insulet has a one year low of $230.05 and a one year high of $353.50. The company has a market capitalization of $22.51 billion, a price-to-earnings ratio of 97.21, a price-to-earnings-growth ratio of 2.64 and a beta of 1.39. The company has a fifty day moving average of $325.06 and a two-hundred day moving average of $309.40. The company has a debt-to-equity ratio of 0.64, a current ratio of 2.26 and a quick ratio of 1.81.

Insider Transactions at Insulet

In related news, SVP Laetitia Cousin sold 797 shares of Insulet stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $348.81, for a total transaction of $278,001.57. Following the transaction, the senior vice president owned 3,890 shares of the company’s stock, valued at $1,356,870.90. The trade was a 17.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, SVP Prem Singh sold 687 shares of the stock in a transaction on Monday, September 8th. The shares were sold at an average price of $347.49, for a total value of $238,725.63. Following the completion of the sale, the senior vice president directly owned 3,456 shares of the company’s stock, valued at $1,200,925.44. The trade was a 16.58% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 0.39% of the stock is currently owned by insiders.

Institutional Trading of Insulet

Several institutional investors have recently made changes to their positions in the company. Worldquant Millennium Advisors LLC purchased a new stake in shares of Insulet during the second quarter worth about $80,082,000. Sei Investments Co. raised its position in Insulet by 27.4% during the 2nd quarter. Sei Investments Co. now owns 137,643 shares of the medical instruments supplier’s stock valued at $43,245,000 after purchasing an additional 29,584 shares during the last quarter. AQR Capital Management LLC raised its position in Insulet by 28.6% during the 2nd quarter. AQR Capital Management LLC now owns 107,566 shares of the medical instruments supplier’s stock valued at $33,705,000 after purchasing an additional 23,948 shares during the last quarter. Quantinno Capital Management LP lifted its holdings in Insulet by 68.3% in the 2nd quarter. Quantinno Capital Management LP now owns 47,681 shares of the medical instruments supplier’s stock worth $14,981,000 after buying an additional 19,355 shares during the period. Finally, State of Tennessee Department of Treasury grew its position in shares of Insulet by 64.6% in the 2nd quarter. State of Tennessee Department of Treasury now owns 45,604 shares of the medical instruments supplier’s stock worth $14,328,000 after buying an additional 17,890 shares during the last quarter.

Analyst Ratings Changes

Several equities analysts recently weighed in on the stock. Stifel Nicolaus initiated coverage on shares of Insulet in a report on Tuesday, October 21st. They issued a “buy” rating and a $370.00 price objective on the stock. Oppenheimer upped their target price on shares of Insulet from $324.00 to $365.00 and gave the stock an “outperform” rating in a research note on Monday, September 8th. Sanford C. Bernstein lifted their target price on Insulet from $400.00 to $410.00 in a research report on Friday. Wolfe Research raised their target price on shares of Insulet from $350.00 to $375.00 and gave the company an “outperform” rating in a research note on Friday. Finally, UBS Group upped their price objective on shares of Insulet from $320.00 to $355.00 and gave the company a “neutral” rating in a report on Friday. One investment analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and three have given a Hold rating to the company. According to MarketBeat, Insulet has an average rating of “Moderate Buy” and an average target price of $370.76.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.